SmartPeptide
Start Free
CognitiveAnimal / preclinical only

Dihexa (PNB-0408)

Synthetic peptidomimetic derived from angiotensin IV. Strong preclinical evidence for synaptogenesis (promoting new synapse formation) — described in animal studies as orders of magnitude more potent than BDNF in some assays. Of intense biohacking interest. NO human clinical trial data published.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Strong rodent and ex-vivo work demonstrating synaptogenic activity at very low doses. Mechanism involves c-Met receptor signaling. No published human clinical trials of any phase.

What's still experimental

All human use. Dose, route (oral vs. transdermal), duration, and safety are completely uncharacterized in humans.

Anecdotal / community reports

Nootropic communities use Dihexa for cognitive enhancement, post-injury recovery, neurodegenerative concerns. Self-experimentation logs vary widely and confound with other interventions.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “Dihexa (PNB-0408)”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

No established dose range

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

No FDA-approved or established trial dose range for this peptide. Anecdotal ranges discussed in community forums exist but are not supported by published clinical trials, and SmartPeptide will not publish unverified doses.

This is the honest answer for peptides like BPC-157, IGF-1 LR3, MOTS-c, Epitalon and similar research compounds — robust human dose- ranging studies have not been published. Always work with a licensed clinician familiar with experimental peptides if you are considering any use.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
No FDA enforcement actions (recalls, market withdrawals, safety alerts) on record for “Dihexa (PNB-0408)”. This is the expected baseline for most peptides — the absence of recalls does NOT imply general safety, only that no formal FDA enforcement has been initiated against approved formulations.

Mechanism & targets

ChEMBL · UniProt · Open Targets

Molecule (ChEMBL)

View on ChEMBL
Formula
C20H19F2N3O3

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
18
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
0
0 total registered

Europe PMC — 396,554 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
327,207
all years
Last 5 years
146,135
recent activity
Open access
310,305
freely readable
OA share
95%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Semantic Scholar API is currently rate-limited.

Human-study summaries for “dihexa OR PNB-0408 OR N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide” are available on Semantic Scholar but the shared free-tier API quota is exhausted right now. Try refreshing in a few minutes, or check the PubMed and Europe PMC panels above for the same literature.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
90,615
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • National Natural Science Foundation of China1,469 works
  • yok264 works
  • Japan Society for the Promotion of Science262 works
  • National Institutes of Health224 works
  • Yok185 works
  • National Science Foundation159 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 6 of 2,071 preprints indexed by Europe PMC.

Known risks

Essentially unknown in humans. No Phase 1 safety data. Theoretical concerns about uncontrolled synapse formation. Source quality / purity is unverifiable.

Reported side effects

Unknown in humans. Anecdotal reports include headache, mild anxiety, sleep disruption.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
No reports found in the FDA Adverse Event Reporting System for “Dihexa (PNB-0408)”. This is normal for research-only peptides that are not marketed as FDA-approved drugs.

What requires medical supervision

Not approved. No clinician oversight available because there's no clinical trial infrastructure in humans.

Questions for your clinician

  • Am I aware there are zero published human trials?
  • What evidence-based cognitive interventions should we exhaust first?
  • What would even constitute 'monitoring' for safety?

Editorially curated references

Discussions about Dihexa (PNB-0408)

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all Dihexa (PNB-0408) discussions Native, moderated, no buying or selling